MYGN logo

Myriad Genetics, Inc. Stock Price

NasdaqGS:MYGN Community·US$697.8m Market Cap
  • 2 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author

MYGN Share Price Performance

US$7.50
-17.60 (-70.12%)
1.7% overvalued intrinsic discount
US$7.38
Fair Value
US$7.50
-17.60 (-70.12%)
2.6% overvalued intrinsic discount
US$7.31
Fair Value
Price US$7.50
AnalystConsensusTarget US$7.31
AnalystLowTarget US$3.50

MYGN Community Narratives

AnalystConsensusTarget·
Fair Value US$7.38 3.6% overvalued intrinsic discount

Expanding Oncology Testing And Genomic Profiling Will Widen Market Reach

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystLowTarget·
Fair Value US$3.5 118.3% overvalued intrinsic discount

Tightening Privacy Laws And Fierce Competition Will Undermine Genetic Testing

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent MYGN News & Updates

Estimating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)

Sep 30
Estimating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)

Myriad Genetics, Inc. (NASDAQ:MYGN) Held Back By Insufficient Growth Even After Shares Climb 28%

Aug 17
Myriad Genetics, Inc. (NASDAQ:MYGN) Held Back By Insufficient Growth Even After Shares Climb 28%

Myriad Genetics, Inc. (NASDAQ:MYGN) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Jun 25
Myriad Genetics, Inc. (NASDAQ:MYGN) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Myriad Genetics, Inc. Key Details

US$832.9m

Revenue

US$246.3m

Cost of Revenue

US$586.6m

Gross Profit

US$981.8m

Other Expenses

-US$395.2m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-4.25
Gross Margin
70.43%
Net Profit Margin
-47.45%
Debt/Equity Ratio
15.3%

Myriad Genetics, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Excellent balance sheet and good value.

2 Risks
2 Rewards

About MYGN

Founded
1991
Employees
2700
CEO
Samraat Raha
WebsiteView website
www.myriad.com

Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; Memorial Sloan Kettering Cancer Center; the University of Texas MD Anderson Cancer Center; the University of Rochester Medical Center; and Flatiron Health, Inc. The company has a strategic alliance with SOPHiA GENETICS SA for the development of liquid biopsy companion diagnostic (CDx) test. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: -2.8%
  • 3 Months: 5.3%
  • 1 Year: 13.4%
  • Year to Date: 11.7%
Over the last 7 days, the market has dropped 2.8%, driven by a pullback of 2.5% in the Information Technology sector. As for the longer term, the market has actually risen by 13% in the last year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›